Lefamulin Acetate Patent Expiration

Lefamulin Acetate is used for treating community-acquired bacterial pneumonia in adults. It was first introduced by Nabriva Therapeutics Ireland Dac in its drug Xenleta on Aug 19, 2019.


Lefamulin Acetate Patents

Given below is the list of patents protecting Lefamulin Acetate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xenleta US6753445 Pleuromutilin derivatives having antibacterial activity Jul 09, 2021

(Expired)

Nabriva
Xenleta US8071643 Pleuromutilin derivatives for the treatment of diseases mediated by microbes Jan 16, 2029 Nabriva
Xenleta US8153689 Pleuromutilin derivatives for the treatment of diseases mediated by microbes Mar 19, 2028 Nabriva
Xenleta US9120727 Process for the preparation of pleuromutilins May 23, 2031 Nabriva


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lefamulin Acetate's patents.

Given below is the list recent legal activities going on the following patents of Lefamulin Acetate.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 12th Yr, Small Entity 02 Oct, 2023 US8153689
Payment of Maintenance Fee, 12th Yr, Small Entity 23 May, 2023 US8071643
Payment of Maintenance Fee, 8th Yr, Small Entity 22 Feb, 2023 US9120727
Patent Term Extension Certificate 15 Feb, 2023 US8071643
Withdrawal of Application for PTE 14 Feb, 2023 US9120727
Withdrawal of Application for PTE 14 Feb, 2023 US8153689
Notice of Final Determination -Election Required 05 Jan, 2023 US8071643
Notice of Final Determination -Election Required 05 Jan, 2023 US8153689
Notice of Final Determination -Election Required 05 Jan, 2023 US9120727
transaction for FDA Determination of Regulatory Review Period 28 Sep, 2022 US8071643



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳